Exagen (XGN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The annual meeting is scheduled for June 10, 2025, with voting on key proposals and director elections.
Shareholders can vote online, by phone, mail, or in person, with detailed instructions provided.
Proxy materials are primarily distributed electronically to reduce costs and environmental impact.
Voting matters and shareholder proposals
Four proposals: election of two Class III directors, ratification of BDO USA, P.C. as auditor, advisory vote on executive compensation, and advisory vote on frequency of future say-on-pay votes.
Board recommends voting for all proposals and for annual say-on-pay votes.
Shareholders may submit proposals for the 2026 meeting by specified deadlines and procedures.
Board of directors and corporate governance
Board consists of seven members, with a majority deemed independent under Nasdaq rules.
Board is divided into three classes with staggered three-year terms; removal only for cause by two-thirds vote.
Committees: Audit, Compensation, and Nominating & Corporate Governance, each with defined charters and independence.
Annual board and committee evaluations are conducted.
Code of Conduct and Ethics and insider trading policy are in place.
Latest events from Exagen
- 2025 revenue rose 20% to $66.6M, with improved margins and strong AVISE CTD test growth.XGN
Q4 202510 Mar 2026 - Record Q2 revenue, margin gains, and raised outlook signal progress toward profitability.XGN
Q2 20242 Feb 2026 - Record revenue, margin gains, and new test enhancements set up cash flow positivity by 2025.XGN
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Q3 2024 saw higher ASP, narrowed losses, and new biomarkers set up for 2025 profitability.XGN
Q3 202414 Jan 2026 - Turnaround delivers ASP growth, new products, and a path to cash flow positivity in 2024.XGN
TD Cowen 45th Annual Healthcare Conference30 Dec 2025 - Record revenue, margin expansion, and new biomarkers set up for profitable growth in 2025.XGN
Q4 202426 Dec 2025 - Registering 1,150,000 shares for resale linked to a $75M term loan and warrant agreement.XGN
Registration Filing16 Dec 2025 - Director elections, auditor ratification, and say-on-pay votes headline the 2025 agenda.XGN
Proxy Filing2 Dec 2025 - Record Q1 revenue of $15.5M, higher ASP, and new credit facility support 2025 growth.XGN
Q1 202523 Nov 2025